Related Experiment Video
Updated: Oct 16, 2025
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.6K
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
Samantha Bruno1, Lorenza Bandini2, Agnese Patuelli2
1Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Frontiers in Oncology
|October 18, 2021
Summary
A novel FMS-like tyrosine kinase 3 (FLT3) deletion mutation was identified in acute myeloid leukemia (AML). This FLT3 mutation is pathogenic and sensitive to the targeted therapy midostaurin.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML), affecting approximately 30% of patients.
- Activating FLT3 mutations include internal tandem duplications (ITD) in the juxtamembrane (JM) domain and tyrosine kinase domain (TKD) point mutations.
- Midostaurin is the only approved FLT3 inhibitor for newly diagnosed AML with FLT3 mutations.
